Long-term Low-Molecular-Weight Heparin versus Usual Care in Proximal-Vein Thrombosis Patients with Cancer Russell D. Hull, MBBS, MSc, Graham F. Pineo, MD, Rollin F. Brant, PhD, Andrew F. Mah, BSc, Natasha Burke, BSc, Richard Dear, MD, Turnly Wong, MD, Roy Cook, MD, Susan Solymoss, MD, Man-Chiu Poon, MD, MSc, Gary Raskob, PhD The American Journal of Medicine Volume 119, Issue 12, Pages 1062-1072 (December 2006) DOI: 10.1016/j.amjmed.2006.02.022 Copyright © 2006 Elsevier Inc. Terms and Conditions
Figure 1 Participant flow chart. The American Journal of Medicine 2006 119, 1062-1072DOI: (10.1016/j.amjmed.2006.02.022) Copyright © 2006 Elsevier Inc. Terms and Conditions
Figure 2 Time to event analysis for patients who had recurrent venous thromboembolism. The American Journal of Medicine 2006 119, 1062-1072DOI: (10.1016/j.amjmed.2006.02.022) Copyright © 2006 Elsevier Inc. Terms and Conditions
Figure 3 Time to event analysis for patients who died. The American Journal of Medicine 2006 119, 1062-1072DOI: (10.1016/j.amjmed.2006.02.022) Copyright © 2006 Elsevier Inc. Terms and Conditions
Figure 4 Randomized clinical trials of long-term low-molecular-weight heparin therapy combined with vitamin-k-antagonist therapy in cancer patients with venous thromboembolism. The American Journal of Medicine 2006 119, 1062-1072DOI: (10.1016/j.amjmed.2006.02.022) Copyright © 2006 Elsevier Inc. Terms and Conditions